Mostrar o rexistro simple do ítem

dc.contributor.authorKong, W.K.F.
dc.contributor.authorSalsano, A.
dc.contributor.authorGiacobbe, D.R.
dc.contributor.authorPopescu, B.A.
dc.contributor.authorLaroche, C.
dc.contributor.authorDuval, X.
dc.contributor.authorSchueler, R.
dc.contributor.authorMoreo, A.
dc.contributor.authorColonna, P.
dc.contributor.authorPiper, C.
dc.contributor.authorCalvo Iglesias, Francisco 
dc.contributor.authorBadano, L.P.
dc.contributor.authorSrdanovic, I.
dc.contributor.authorBoutoille, D.
dc.contributor.authorHuttin, O.
dc.contributor.authorStöhr, E.
dc.contributor.authorTimóteo, A.T.
dc.contributor.authorVaskelyte, J.J.
dc.contributor.authorSadeghpour, A.
dc.contributor.authorTornos, P.
dc.contributor.authorAbid, L.
dc.contributor.authorPoh, K.K.
dc.contributor.authorHabib, G.
dc.contributor.authorLancellotti, P.
dc.date.accessioned2025-08-26T11:22:47Z
dc.date.available2025-08-26T11:22:47Z
dc.date.issued2022
dc.identifier.citationKong WKF, Salsano A, Giacobbe DR, Popescu BA, Laroche C, Duval X, et al. Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry. European Heart Journal. 2022;43(29):2770-80.
dc.identifier.issn1522-9645
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/636708d9688cd71757e141ea*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20924
dc.description.abstractAim: Fatality of infective endocarditis (IE) is high worldwide, and its diagnosis remains a challenge. The objective of the present study was to compare the clinical characteristics and outcomes of patients with culture-positive (CPIE) vs. culture-negative IE (CNIE). Methods and results: This was an ancillary analysis of the ESC-EORP EURO-ENDO registry. Overall, 3113 patients who were diagnosed with IE during the study period were included in the present study. Of these, 2590 (83.2%) had CPIE, whereas 523 (16.8%) had CNIE. As many as 1488 (48.1%) patients underwent cardiac surgery during the index hospitalization, 1259 (48.8%) with CPIE and 229 (44.5%) with CNIE. The CNIE was a predictor of 1-year mortality [hazard ratio (HR) 1.28, 95% confidence interval (CI) 1.04-1.56], whereas surgery was significantly associated with survival (HR 0.49, 95% CI 0.41-0.58). The 1-year mortality was significantly higher in CNIE than CPIE patients in the medical subgroup, but it was not significantly different in CNIE vs. CPIE patients who underwent surgery. Conclusion: The present analysis of the EURO-ENDO registry confirms a higher long-term mortality in patients with CNIE compared with patients with CPIE. This difference was present in patients receiving medical therapy alone and not in those who underwent surgery, with surgery being associated with reduced mortality. Additional efforts are required both to improve the aetiological diagnosis of IE and identify CNIE cases early before progressive disease potentially contraindicates surgery.en
dc.description.sponsorshipThe study has received funding from Abbott Vascular Int. (2011-2021), Amgen Cardiovascular (2009-2018), AstraZeneca (2014-2021), Bayer AG (2009-2018), Boehringer Ingelheim (2009-2019), Boston Scientific (2009-2012), The Bristol Myers Squibb and Pfizer Alliance (2011-2019), Daiichi Sankyo Europe GmbH (2011-2020), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014-2017), Edwards (2016-2019), Gedeon Richter Plc. (2014-2016), Menarini Int. Op. (2009-2012), MSD-Merck & Co. (2011-2014), Novartis Pharma AG (2014-2020), ResMed (2014-2016), Sanofi (2009-2011), SERVIER (2009-2021), and Vifor (2019-2022).en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleOutcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry*
dc.typeArticleen
dc.authorsophosKong, P. W. K. F.
dc.authorsophosSalsano, A.
dc.authorsophosGiacobbe, D. R.
dc.authorsophosPopescu, B. A.
dc.authorsophosLaroche, C.
dc.authorsophosDuval, X.
dc.authorsophosSchueler, R.
dc.authorsophosMoreo, A.
dc.authorsophosColonna, P.
dc.authorsophosPiper, C.
dc.authorsophosCalvo-Iglesias, F.
dc.authorsophosBadano, L. P.
dc.authorsophosSrdanovic, I.
dc.authorsophosBoutoille, D.
dc.authorsophosHuttin, O.
dc.authorsophosStöhr, E.
dc.authorsophosTimóteo, A. T.
dc.authorsophosVaskelyte, J. J.
dc.authorsophosSadeghpour, A.
dc.authorsophosTornos, P.
dc.authorsophosAbid, L.
dc.authorsophosPoh, K. K.
dc.authorsophosHabib, G.
dc.authorsophosLancellotti
dc.identifier.doi10.1093/eurheartj/ehac307
dc.identifier.sophos636708d9688cd71757e141ea
dc.issue.number29
dc.journal.titleEuropean Heart Journal*
dc.page.initial2770
dc.page.final2780
dc.relation.projectIDAbbott Vascular Int.; Amgen Cardiovascular; AstraZeneca; Bayer AG; Boehringer Ingelheim; Boston Scientific; Bristol Myers Squibb; Pfizer Alliance; Daiichi Sankyo Europe GmbH; Alliance Daiichi Sankyo Europe GmbH; Eli Lilly and Company; Edwards; Gedeon Richter Plc; Menarini Int. Op; MSD-Merck Co.; Novartis Pharma AG; ResMed; Sanofi; SERVIER; Vifor
dc.relation.publisherversionhttps://academic.oup.com/eurheartj/article-pdf/43/29/2770/49880595/ehac307.pdf;https://watermark.silverchair.com/ehac307.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA2IwggNeBgkqhkiG9w0BBwagggNPMIIDSwIBADCCA0QGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMbf0C7T3HHPe9_SI5AgEQgIIDFWJQD7qUqYDt1jGSz1x0JSlsg70ykh-uCbhW9kG_zbwQVPimYNsCiWqAH9wWnKbK4wq0rpEvrLZ5LBkm6hUHCG-k6nDaF1bj7gWv00e0LueP7yNg2HvIk0SKCWV9iUb_FFX0ENGyVrDpYzHgWIYb0ARVUx7F0V87VUJFWq0Q67g-evLT-pOKlw0iPPwsuL9-iH4rJV5SpIn8Xh9o-NRwFIhZTJKO7ypLCXOrGmmxHR4AiT0Nu0cDamg0jWVb3Kz67hnREQXcJc3cU5-iXYy68EObUZlzbYXDxC2Y_sVtQ6fYuahxeErL_lXfPy6U67GTzG_frMg8v83RBhq1tx_muxi0pJL8ihHEEsAuLPUEwzH1k5KEmrREMuOAixqgKousdNxSg4QcUmVBpENfSCREm5QOb61nvtmx52ecMvM99KACxsI-Jesgi-6M082In55qgmIMltgtNzpTJXTlDNjTv8AKlLOuPK98SiTkoA3HRmEGbFDV5WI16n9rw38YEmDlC9eLsi7dmSXCvPnBh1Bmo8Y68ziC5iZheYN1FsUWyTRcFQPmQzMvKEhE1eE_5BHH2Ck32mzwgRE-JeWqaaE-DQd0y5HWxr1VoLvp5pmTpBxuD-3l3DpKiAWHZaUCBcGgPWeZonLdfZ73UEDGpfsqQqXFFOnCT0bq3VyhpdvU89YV-WyZqgKemUASuiRcsjGVZtUB6Q8uMSXAX8_K6BdGTD2M7qVMlDQ-9FvKag-W4Nw3gSCwKY0ODW1j6MejDc6mLdiZea-goM9-vfUs8wOjDKfA2cJ1qVgugQuC9L9azzmCB6MwUHKqHgMvOftZFUmuXoDwFs6lKAAcYFbPA84JMH57fVHGNABBl1kXOxeg61Dyh2FzmjRoPoQ-B0wQAy3Cp1NnnZs8kZanxAr3KXUUFNkBvjUuLbvWW-GZf-_HGXdPICmT7Up0QiIikBMTaZ-gDvSFpfUqo8nRFzuBoL4MEzCIR5EO_D8vDgMt0_NLSNzqh3Tn0jhC5Bd1TQW-s0ryKY82-oKo4MiReTVZOSzPrvcOj96xRwes
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Vigoes
dc.subject.keywordCHUVIes
dc.subject.keywordIISGSes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number43


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Atribución 4.0 Internacional
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAtribución 4.0 Internacional